DioGenix plans to use $1.5 million it raised last month in series B financing to support a multi-center prospective clinical trial of its targeted B-cell sequencing test for early diagnosis of multiple sclerosis.

DioGenix recently completed a mostly retrospective study of its cerebrospinal fluid targeted sequencing approach, which showed that the test performed with double the specificity and about the same sensitivity as current methods for testing CSF such as oligoclonal banding.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.